Moxifloxacin: new indication. Do not use in gynaecological infections or other conditions.
In pelvic inflammatory disease, fluoroquinolones are not first-line drugs and moxifloxacin is the worst of these drugs.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001372:Aza Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004716:Endometritis / Q000188:drug therapy*; D005060:Europe; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D000077266:Moxifloxacin; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy*; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012488:Salpingitis / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin